Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Retrieved on:
星期六, 六月 10, 2023
IIT, CD19, SCR, European Hematology Association, CRS, DLBCL, B-cell maturation antigen, NHL, Cancer, SLE, B-cell lymphoma, MRD, Congress, Patient, Graceling, SAN, Autoimmune disease, Cytokine release syndrome, EHA, CR, Phenotype, ORR, BCMA, Safety, April 12, Vaccine, Pharmaceutical industry, Tanning (leather), Medical imaging, RRMM
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, June 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented longer-term follow-up data from a first-in-human study evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate, in patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma (r/r B-NHL) as an oral presentation (abstract #S234) at the European Hematology Association (EHA2023) Congress.
Key Points:
- GC012F is manufactured through a novel next-day FasTCAR process and demonstrated a younger phenotype of CAR-T cells and highly effective tumor killing activity in preclinical animal models.
- In the single-arm, open label investigator-initiated trial (IIT), nine r/r B-NHL patients were enrolled and treated with GC012F, and completed at least three months of follow-up.
- All patients’ lymphoma samples expressed CD19, and samples from seven out of eight tested patients expressed BCMA.
- GC012F also continued to show a favorable safety profile:
Cytokine release syndrome (CRS) was mostly Grade 1 (56%; 5/9).